A Study For The Clinical Applications Of Serum Anti-p53 Antibodies Detection During The Neoadjuvantchemotherapy Treatment Of Breast Cancer Patients

Breast carcinoma is one of the most common malignancies in women. Every year, more than 1,000,000 people are sufferring from this disease worldwide. Previous data indicated that the incidence of breast cancer was increasing by 0.2% to 3% every year. In 1992, there were 180,000 breast carcinoma patients in the US, and the incidence was as high as 1.11%. According to statistical data, in 1994, 110,635 new entrants suffered from breast carcinoma, and the incidence was 0.2%. Moreover, 27,343 people dead from this disease. The number of patients who lost breast and dead continues increasing year by year. Following popularization and enhancement knowledge of cancer prevention, improvement of medical science, amelioration of medical installation, several mastopathia could be controlled, especially breast carcinoma. Recently, as more and more technical innovations are used to prevention and earlier diagnosis, combined therapeutic efficacy on breast carcinoma has made significant achievement.In the 70^th and 80^th of 20 century, much clinical evidence indicted that chemotherapy could promote higher survival rate and quality. As a pantosomatous adjunctive therapeutic strategy, chemotherapy is as important as surgery, radiotherapy and endocrine therapy to treat breast cancer, they have equally clinical value. Chemotherapy has became one principal method to therapy invasive breast cancer. Neoadjuvant chemotherapy(NAC) is commonly used as a systemic treatment of locally advanced breast cancer. This treatment is usually given to downstage tumors and promotes higher conservative breast surgery rates. Although neoadjuvant chemotherapy for breast cancer has been used in clinic for a long time, it's unclear that the function of tumor biomakers during the treatment process of NAC.Many investigations have suggested that the anti-p53 antibodies(Abs) would be detected in the earlier stage of neoplasia. In this experiment, used the gene recombination technology, the wild-type p53 protein was expressed and purified. Using the ELISA approach, we detected 86 patients with breast cancer, and the respectively was 95%. The relationship between the expression of serum p53 antibody and patients' characteristics was investigated, and we found some correlation between the p53 Abs expression and these characteristics. Besides, the result showed that, before the NAC treatment, patients who were p53 Abs negative would obtain a better response to the anti-cancer drugs of anthracycline, while the positive would obtain a bad response. Therefore, the detection of anti-p53 Abs, studying of the relationships between anti-p53 Abs and patients' characteristics, treatment schemes and other tumor biomakers will do a lot of good to the breast cancer's clinical diagnosis, prediction and anti-cancer drug's choice.